How faith leaders like me can help address America's obesity epidemic

AdobeManyfactorsdriveAmerica’sobesityepidemic—environment,genetics,eatinghabits,andmore.Solvingthepr EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad




comprehensive

author：leisure time    Page View：81
ASH19 CAR-T
Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

advertisement

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： Study: Why relieving medical debt did not improve financial outcomes
Next article： United colonoscopy coverage change 'may cost lives,' doctors say